Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Low dose requirement for warfarin treatment in a patient with CYP2C93/13 genotype.

Clinica chimica acta; international journal of clinical chemistry - 20 Nov 2011

Kwon Min-Jung, On Young-Keun, Huh Wooseong, Ko Jae-Wook, Kim Duk-Kyung, Kim June Soo, Lee Soo-Youn

Abstract excerpt

BACKGROUND: Cytochrome P450 2C9 (CYP2C9) is the major isoform of the CYP2C subfamily, and is involved in the metabolism of many clinically important therapeutic agents. Here we describe a patient who was intolerant of warfarin treatment because of impaired drug metabolism related to the CYP2C9*3/*13 genotype and high warfarin sensitivity associated with the VKORC1 1173TT genotype. CASE: A 64-year-old Korean man...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticoagulants
Share to Aryl Hydrocarbon Hydroxylases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Dose-Response Relationship, Drug

Share to VKORC1 gene

Share to Genotype

Share to Warfarin

Source

Identifiers

PMID: 21782804
DOI: 10.1016/j.cca.2011.06.040

Genes

VKORC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Low dose requirement for warfarin treatment in a patient with CYP2C9*3/*13 genotype.PMID 21782804Read ↗

A case report of a patient carrying CYP2C9*3/4 genotype with extremely low warfarin dose requirement.Semantic proximity Read ↗

Warfarin dose requirement for patients with both VKORC1 3673A/A and CYP2C9*3/*3 genotypes.Semantic proximity Read ↗

Extremely low warfarin dose in patients with genotypes of CYP2C9*3/*3 and VKORC1-1639A/A.Semantic proximity Read ↗

Warfarin dosing and cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

Pharmacogenetic distribution of warfarin and its clinical significance in Korean patients during initial anticoagulation therapy.Semantic proximity Read ↗

Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients.Semantic proximity Read ↗

Warfarin dose requirements in a patient with the CYP2C9*14 allele.Semantic proximity Read ↗

Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.Semantic proximity Read ↗

First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.Semantic proximity Read ↗

Extremely elevated international normalized ratio of warfarin in a patient with CYP2C9*1/*3 and thyrotoxicosis.Semantic proximity Read ↗

Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.Semantic proximity Read ↗

Standard warfarin dose in a patient with the CYP2C9*3/*3 genotype leads to hematuria.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.